Skip to content
The Injury Atlas
HTN

Hypertension

Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.

24signature agents

Where it strikes

Vasculature / Endothelium

Glomerular & peritubular capillaries

Glomerulus

Filtration barrier (podocytes + endothelium)

See it on the nephron

Agents’ overall severity

Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.

Moderate· 16Mild· 8

Agents’ overall reversibility

Partially reversible· 2Variable· 5Reversible· 17
Does the kidney recover? Cross-drug outcomes

Agents’ onset window

How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.

Hyperacute (<24 h)· 1Acute (days)· 1Subacute (weeks)· 16Delayed (weeks–months)· 2Variable· 4

Real-world reporting for this lesion

FAERS across all lesions →

How disproportionately hypertension is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.

29Corroborated

Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.

7Documented, FAERS-silent

Documented in a profile with no reporting signal. 5 of 7 sit on a reportable term with enough reports, so FAERS could have flagged the lesion and did not; the rest are expected silences.

14Not attributable

A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.

20Reported by name

The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.

Order
  1. LenvatinibVEGFR TKI13.61 (13.27–13.96) · n=7,510 Reporting signal.
  2. NiraparibPARP inhibitor10.09 (9.74–10.46) · n=3,641 Reporting signal.
  3. TivozanibVEGFR TKI9.89 (8.61–11.36) · n=235 Reporting signal.
  4. OctreotideSomatostatin analog · FAERS only9.38 (9.09–9.67) · n=4,759 Reporting signal.
  5. NaxitamabAnti-GD2 antibody8.87 (6.25–12.57) · n=37 Reporting signal.
  6. VandetanibVEGFR/EGFR/RET TKI7.18 (6.04–8.54) · n=144 Reporting signal.
  7. FruquintinibVEGFR TKI7.00 (6.36–7.71) · n=475 Reporting signal.
  8. AxitinibVEGFR TKI6.63 (6.34–6.93) · n=2,235 Reporting signal.
  9. CabozantinibVEGFR/MET TKI6.39 (6.21–6.57) · n=5,301 Reporting signal.
  10. PralsetinibRET inhibitor5.73 (4.92–6.67) · n=184 Reporting signal.
  11. RegorafenibVEGFR TKI5.65 (5.32–6.01) · n=1,155 Reporting signal.
  12. SorafenibVEGFR TKI4.75 (4.53–4.99) · n=1,757 Reporting signal.
  13. CopanlisibPan-PI3K inhibitor4.58 (3.16–6.64) · n=30 Reporting signal.
  14. SunitinibVEGFR TKI4.55 (4.38–4.72) · n=3,180 Reporting signal.
  15. SelpercatinibRET inhibitor4.44 (3.63–5.44) · n=101 Reporting signal.
  16. PazopanibVEGFR TKI4.34 (4.16–4.54) · n=2,106 Reporting signal.
  17. PonatinibBCR-ABL TKI3.81 (3.53–4.11) · n=714 Reporting signal.
  18. PexidartinibCSF1R inhibitor · FAERS only3.74 (2.80–5.00) · n=49 Reporting signal.
  19. RipretinibKIT switch-control inhibitor3.45 (3.09–3.86) · n=332 Reporting signal.
  20. BevacizumabAnti-VEGF antibody3.42 (3.34–3.50) · n=8,088 Reporting signal.
  21. RituximabAnti-CD20 antibody · FAERS only3.29 (3.23–3.35) · n=12,891 Reporting signal.
  22. VimseltinibCSF1R tyrosine kinase inhibitor · FAERS only3.26 (2.30–4.64) · n=33 Reporting signal.
  23. RaltitrexedAntifolate (TS inhibitor) · FAERS only3.03 (2.15–4.28) · n=34 Reporting signal.
  24. BrigatinibALK TKI2.86 (2.48–3.31) · n=194 Reporting signal.
  25. LanreotideSomatostatin analog · FAERS only2.74 (2.48–3.03) · n=405 Reporting signal.
  26. PenpulimabPD-1 immune checkpoint inhibitor · FAERS only2.74 (1.12–6.75) · n=5 Reporting signal, fragile (few reports).
  27. PembrolizumabPD-1 checkpoint inhibitor · FAERS only2.59 (2.51–2.66) · n=4,694 Reporting signal.
  28. AsciminibBCR-ABL STAMP inhibitor2.43 (2.06–2.88) · n=144 Reporting signal.
  29. EverolimusmTOR inhibitor · FAERS only2.33 (2.23–2.43) · n=2,159 Reporting signal.
  30. Methotrexate (high-dose)Antifolate · FAERS only2.14 (2.11–2.17) · n=19,305 Reporting signal.
  31. RamucirumabAnti-VEGFR2 antibody2.02 (1.78–2.30) · n=241 Reporting signal.
  32. CarfilzomibProteasome inhibitor1.84 (1.73–1.96) · n=986 Reporting signal.
  33. NintedanibVEGFR/FGFR/PDGFR TKI1.78 (1.67–1.89) · n=1,102 Reporting signal.
  34. DinutuximabAnti-GD2 antibody1.78 (1.23–2.58) · n=29 Reporting signal.
  35. AbirateroneCYP17 inhibitor1.58 (1.49–1.67) · n=1,233 Reporting signal.
  36. IbrutinibBTK inhibitor1.45 (1.39–1.51) · n=2,237 Reporting signal.
  37. EnzalutamideAndrogen-receptor inhibitor1.41 (1.34–1.49) · n=1,585 Reporting signal.
  38. Trastuzumab emtansine (T-DM1)Antibody-drug conjugate (HER2/DM1)1.35 (1.18–1.54) · n=218 Reporting signal.
  39. Ziv-afliberceptVEGF trap1.24 (1.15–1.33) · n=773 Reporting signal.
  40. AcalabrutinibBTK inhibitor0.93 (0.82–1.06) · n=228 No reporting signal.
  41. GemcitabineNucleoside analog0.78 (0.73–0.84) · n=816 No reporting signal.
  42. LeuprolideGnRH agonist0.73 (0.69–0.78) · n=1,131 No reporting signal.
  43. TrametinibMEK inhibitor0.62 (0.56–0.70) · n=294 No reporting signal.

reporting odds ratio (log) — no signal left of the dashed line at 1.0

No ratio — no HTN reports, or too few (count in brackets): Relacorilant

No ratio — under 50 FAERS reports in total: Ivonescimab, Olverembatinib

No FAERS reports under the agent's name: Iobenguane I-131

All 37 agents documented with HTN in the atlas are shown whether or not FAERS flags them, plus the 34 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib)) are not asked of FAERS; their member agents are ranked individually. 63 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.

Management approach

Full framework →

An expected effect (on-target with VEGF-pathway agents) — treat the blood pressure and usually continue the drug.

Drug-level levers

  • Continue the agent if blood pressure is controlled (with VEGF-pathway agents, hypertension correlates with on-target activity).
  • Hold for severe/refractory hypertension or a hypertensive emergency; resume once controlled.
  • Dose-reduce for grade 3 hypertension not controlled on therapy.

Pharmacologic toolkit

  • Antihypertensives — An ACE inhibitor/ARB (also helps any proteinuria) and/or a dihydropyridine calcium-channel blocker are common first choices; avoid non-dihydropyridine CCBs with CYP3A4-metabolized TKIs.

When to biopsy

Not indicated for isolated hypertension.

Monitoring

  • · Home and clinic blood pressure, especially in the first cycles
  • · Urine protein

Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.

What the guidelines say

All guidelines →

Society and consensus recommendations that speak to hypertension.

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

KDIGOManagement of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice GuidelineAnn Intern Med 2021 · PMID 34152826Recommends standardized office BP measurement and a target systolic BP <120 mm Hg for most CKD patients, with RAAS inhibitors first-line when albuminuria is present — the BP-management basis for anti-VEGF/TKI-induced hypertension and proteinuria.ESC2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Eur Heart J 2022 · PMID 36017568For VEGF/VEGFR inhibitors, perform baseline cardiovascular risk assessment, monitor blood pressure (weekly during the first cycle, then regularly) and treat to a target <140/90 mmHg with ACE inhibitors/ARBs and dihydropyridine calcium-channel blockers; manage VEGFi-associated hypertension and proteinuria with interruption/dose modification when severe.ESCEuropean Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatmentEur Heart J Qual Care Clin Outcomes 2022 · PMID 36316010Adherence quality indicators require documented baseline cardiovascular risk assessment and structured monitoring of cardiovascular complications (including hypertension) during cancer therapy such as VEGF-pathway inhibitors.UK Consensus PanelUsing bevacizumab to treat metastatic cancer: UK consensus guidelinesBr J Hosp Med (Lond) 2010 · PMID 21135762Assess and monitor blood pressure and proteinuria during bevacizumab therapy; treat emergent hypertension to standard targets and interrupt/discontinue the drug for uncontrolled hypertension, nephrotic-range proteinuria or other severe vascular toxicity.

Cited incidence across agents

Where the literature gives a representative hypertension figure, the agents ranked highest first. Hover a dot for its cited note.

0%35%70%Lenvatinib: 70% — Meta-analysis (2483 pts): cumulative all-grade HTN 70%, high-grade (>=3) 34%; RR vs comparators 2.61 all-grade / 3.35 high-grade (PMID 35538636)Lenvatinib70%Fruquintinib: 55.4% — 55.4% all-grade, 21.2% grade >=3 (FRESCO phase 3) (PMID 32901330)Fruquintinib55.4%Regorafenib: 44.4% — All-grade hypertension 44.4% (95% CI 30.8-59.0), high-grade 12.5%, in a meta-analysis of 5 trials (n=1,069); RR 3.76 vs control. The signature VEGF-pathway toxicity. (PMID 24150533)Regorafenib44.4%Ziv-aflibercept: 44.2% — All-grade hypertension 44.2% (95% CI 39.7-48.7) and grade III/IV 22.6%, pooled from the single-arm studies of a 10-study (2,889-patient) meta-analysis of aflibercept plus chemotherapy in metastatic colorectal cancer; in its randomized trials, OR 6.30 vs control. (PMID 37657052)Ziv-aflibercept44.2%Ibrutinib: 25.3% — Any-grade hypertension in 25.3% of ibrutinib-treated relapsed/refractory CLL/SLL patients (ALPINE, n=325). (PMID 39316666)Ibrutinib25.3%Axitinib: 24.9% — Grade 3-4 hypertension in 24.9% pooled across axitinib trial arms (a safety meta-analysis that extracted grade 3/4 events only); the estimate leans on one trial and falls to 18.2% without it. (PMID 29353818)Axitinib24.9%Niraparib: 22% — Hypertension ~22% (any grade) with single-agent niraparib 300 mg; a recognized class effect requiring BP monitoring (PMID 31474354)Niraparib22%Sunitinib: 21.6% — All-grade hypertension 21.6% (95% CI 18.7-24.8%), high-grade 6.8%, in a meta-analysis of 4,999 patients on single-agent sunitinib; the signature and by far the most common renal-relevant toxicity of VEGF-pathway blockade. (PMID 18752081)Sunitinib21.6%Ramucirumab: 20% — All-grade hypertension ~20.0% (high-grade ~8.6%) in meta-analysis of 11 studies, n=3,851; RR 2.77 vs control (PMID 25697774)Ramucirumab20%Tivozanib: 20% — Grade 3/4 hypertension in 20% (35/173) — the most common grade 3/4 treatment-related adverse event in the phase III TIVO-3 trial (third/fourth-line metastatic RCC). (PMID 31810797)Tivozanib20%Ponatinib: 14.1% — Hypertension reported in 14.1% of real-world ponatinib-treated CML (part of the arterial-occlusive toxicity profile) (PMID 30892724)Ponatinib14.1%Selpercatinib: 14% — Grade >=3 hypertension in 14% of RET fusion-positive NSCLC patients in LIBRETTO-001, the most common grade >=3 adverse event. (PMID 32846060)Selpercatinib14%Pralsetinib: 11% — Grade >=3 hypertension in 11% (26/233) of RET fusion-positive NSCLC and 17% (24/142) of RET-altered thyroid cancer (ARROW); among the most common grade >=3 treatment-related events (PMID 34118197)Pralsetinib11%
Representative per-agent hypertension incidence where a published figure is citable — open an agent's name for its profile and cited source, or hover its dot for the source inline. Agents without a citable figure are omitted; a tier without a number is not the same as a low number.

Signature offenders

24

Agents for which hypertension is the defining renal lesion.

VEGFR Tyrosine Kinase InhibitorsHypertension within days–weeks; proteinuria over weeks–months.Hypertension ~17–50%; proteinuria 8–73% across agents (the cited review's ranges; it reports no single pooled proteinuria rate).ModerateRamucirumabWithin the first one to two cycles (weeks).Hypertension and proteinuria are common class effects; nephrotic syndrome is a less frequent but reported event, sometimes after only 1-2 doses and typically accompanied by hypertension.ModerateZiv-afliberceptWithin weeks to a few months of therapy.Hypertension and proteinuria are common class effects; in the registrational VELOUR trial, grade 3-4 hypertension and proteinuria were more frequent with aflibercept plus FOLFIRI than with FOLFIRI alone. Nephrotic-range proteinuria and renal thrombotic microangiopathy are documented, including with the ophthalmic formulation, indicating a direct VEGF-trap mechanism. A meta-analysis of 15 trials (4,451 patients) put the summary all-grade hypertension incidence at 42.4%.ModerateLenvatinibWithin the first weeks of therapy (hypertension early; proteinuria over weeks).Hypertension is among the most common adverse events; in the SELECT thyroid-cancer trial hypertension occurred in about 68% (grade >=3 ~42%) and proteinuria in roughly 31%. In KEYNOTE-B61 (lenvatinib plus pembrolizumab) grade 3-4 hypertension occurred in ~23%. Proteinuria is a frequent renal AE with lenvatinib.ModerateCabozantinibWithin weeks of starting therapy.Hypertension and proteinuria are common; in pivotal RCC trials (e.g., METEOR, CABOSUN) hypertension was among the most frequent adverse events with grade >=3 rates around 15-28%. Cabozantinib is one of the TKIs most often associated with proteinuria, with case reports of nephrotic syndrome. Reported rate: grade >=3 hypertension in 15% — Adults with advanced/metastatic clear-cell renal cell carcinoma previously treated with >=1 VEGFR tyrosine-kinase… (Choueiri 2016, PMID 27279544).ModerateRegorafenibWithin the first weeks of therapy.Hypertension is common and frequently grade 3. Pooling 3,813 patients across the cardiovascular-event literature puts all-grade hypertension at 36.8% (95% CI 29.8-43.8%) and high-grade at 9.9% (7.4-12.4%), against controls a relative risk of 4.10 all-grade and 5.82 high-grade. An earlier, smaller meta-analysis of 1,069 patients from five trials (750 on regorafenib) ran higher at 44.4% (30.8-59.0%) all-grade and 12.5% (5.2-27.1%) high-grade, with wider intervals; the CORRECT trial itself reported about 28% (grade 3 ~7%). Proteinuria also occurs as a VEGF-pathway class effect, but is not separately quantified for this agent.ModerateVandetanibWithin the first weeks of therapy.In the pivotal phase III ZETA trial, any-grade hypertension occurred in about 32% of vandetanib-treated patients versus 5% with placebo; proteinuria occurs as an antiangiogenic class effect.ModerateTivozanibWithin the first weeks of therapy.In the phase III TIVO-3 trial, hypertension was the most common grade 3-4 treatment-related adverse event, occurring in about 20% of tivozanib-treated patients; proteinuria occurs as a VEGFR class effect but is comparatively less prominent.ModeratePonatinibHypertension can emerge early; arterial occlusive events accrue over months, with dose reduction mitigating risk.Ponatinib carries a black-box warning for arterial occlusive and thrombotic events and has the highest cardiovascular event rate among CML TKIs (about 41% in one comparative cohort; cumulative arterial occlusive events ~31% over 5 years in the PACE trial). Treatment-emergent hypertension is common; renal injury is largely a downstream consequence of hypertension and vascular disease.ModerateSelpercatinibHypertension within the first weeks to months; creatinine changes early.Hypertension is among the most common adverse events in LIBRETTO-001 (a frequent grade >=3 event), and a reversible serum-creatinine increase is also recognized. A single-center hereditary-MTC series found hypertension in ~26% on selective RET inhibitors. Reported rate: grade >=3 hypertension in 19.7% — 837 patients with RET-activated advanced/metastatic solid tumors receiving selpercatinib monotherapy (20 mg once daily to 240 mg twice daily in phase I, 160 mg twice daily in phase II), median follow-up 45.4 months (Raez 2024, PMID 39471424).ModerateIbrutinibHypertension develops over weeks–months (can be early); tumor lysis is early (first cycle); glomerular/interstitial lesions are case-level over weeks to months.New or worsened hypertension is common (~26% in a real-world CLL cohort comparing it with acalabrutinib; higher with longer follow-up). AKI at CLL presentation and with tumor lysis is well described. Drug-attributable AKI from interstitial nephritis or glomerular endotheliosis is case-level.ModerateFruquintinibWithin weeks of starting therapy (hypertension often earliest).Hypertension and proteinuria are characteristic VEGFR-TKI class effects; in the FRESCO-2 safety analysis hypertension was the most frequent treatment-related adverse event of special interest, occurring in 28.9% of fruquintinib-treated patients all-grade and 10.7% at grade ≥3, with proteinuria also reported (1.3% of patients required a dose reduction for it). Renal-specific TMA is rare but described across the VEGF-inhibitor class.ModerateCopanlisibAcute and infusion-bound — within hours of each dose, resolving within ~24 h.On monotherapy (CHRONOS-1), transient on-infusion-day hypertension occurs in 29.6% all-grade (grade 3 23.9%), and hyperglycemia in 50.0% all-grade (grade 3 33.1%, grade 4 7.0%); with rituximab (CHRONOS-3) the grade 3-4 rates are higher — hypertension 40% and hyperglycemia 56%. Both peak within hours of the infusion and largely resolve by the next day. Sustained renal injury is uncommon.ModerateSunitinibHypertension typically appears early (within the first treatment cycle/weeks); proteinuria develops over weeks to months, and biopsy-proven TMA in case series presented on average around 2 years (range ~7-36 months) into therapy.In a systematic review/meta-analysis of 4,999 patients across 13 trials, all-grade hypertension occurred in ~21.6% and high-grade hypertension in ~6.8% of sunitinib-treated patients, with a significantly increased risk of renal dysfunction versus controls (RR ~1.36); risk varied by tumor type and dosing schedule. Proteinuria is common but less consistently quantified, and severe glomerular lesions (thrombotic microangiopathy, nephrotic-range proteinuria) are reported mainly at the case-series level. Reported figures are class-consistent with other VEGF-pathway inhibitors.ModerateAxitinibHypertension typically emerges early, frequently within days to the first few weeks of starting therapy. Proteinuria tends to develop over weeks of continued exposure and is dose-related. Severe glomerular lesions (TMA, nephrotic syndrome) are usually later and more variable in timing.Hypertension is the dominant and best-quantified renal-relevant signal. In the randomized phase III AXIS trial, treatment-emergent all-causality hypertension occurred in 40.4% of axitinib-treated patients (vs 29.0% with sorafenib), with grade 3 hypertension in 15.3% and grade 4 in 0.3%. A real-world VEGFR-TKI cohort in metastatic RCC similarly found hypertension to be the single most common anti-angiogenesis-related adverse event (about 48.6% in TKI-naive patients across the class). Proteinuria is the next most common renal effect; across the VEGF-inhibitor class mild/asymptomatic proteinuria is reported in roughly 21% to 63% of patients, with heavy (nephrotic-range) proteinuria in up to about 6.5% of RCC patients, and axitinib-specific proteinuria rates have been higher in some populations (e.g., Japanese cohorts). Thrombotic microangiopathy and other glomerular lesions (FSGS-like injury, podocytopathy, hyaline occlusive glomerular microangiopathy) are reported at the severe, biopsy-level end of the spectrum but are not precisely quantified for axitinib specifically.ModerateSorafenibHypertension typically emerges within the first few weeks of treatment; proteinuria develops over weeks to months of continued exposure. Nephrotic syndrome and thrombotic microangiopathy are variable, generally appearing after weeks to months but occasionally sooner.Hypertension is the dominant renal-vascular signal: a systematic review/meta-analysis of 9 trials (4,599 patients) reported an all-grade incidence of 23.4% (95% CI 16.0-32.9%) and high-grade (grade 3-4) incidence of 5.7% (Wu 2008), and a larger meta-analysis of 93 trials (20,494 patients) gave concordant figures of 21.3% all-grade and 5.9% high-grade, with higher rates in renal-cell and thyroid cancer and rising incidence with longer treatment duration (Yang 2017). Proteinuria is a VEGF-pathway class effect: across VEGF-signaling inhibitors mild/asymptomatic proteinuria is reported in roughly 21-63% and heavy (nephrotic-range) proteinuria in up to about 6.5% of renal-cell carcinoma patients (Izzedine 2009); drug-specific quantitative proteinuria data for sorafenib alone are more limited. Nephrotic-range proteinuria and renal-limited thrombotic microangiopathy are documented but uncommon.ModerateNintedanibOver months of therapy in reported cases.Renal effects are uncommon; proteinuria and rare biopsy-proven renal thrombotic microangiopathy have been reported, consistent with VEGF-pathway inhibition. Renal incidence is not well quantified (case-level), and much of the published renal experience comes from pulmonary-fibrosis rather than oncology cohorts.MildNiraparibHypertension typically emerges within the first weeks to months of therapy.Hypertension is a class-distinctive adverse event: a FAERS pharmacovigilance plus RCT meta-analysis estimated ~16.9% any-grade hypertension, disproportionately higher with niraparib than other PARP inhibitors. A small reversible serum-creatinine rise is also seen across the class (pooled OR for creatinine elevation ~5 vs placebo), but grade >=3 nephrotoxicity is <1%.MildPralsetinibHypertension within the first weeks to months.Hypertension is among the more common grade >=3 treatment-related adverse events (about 11% in the ARROW NSCLC cohort); clinically significant intrinsic AKI is rare.MildAcalabrutinibTumor lysis early (first cycle); hypertension over weeks–months.Hypertension occurs but is less frequent than with ibrutinib (~15% vs ~26% in a matched real-world cohort; ELEVATE-RR confirmed lower hypertension and atrial fibrillation head-to-head). One single-center cardio-oncology cohort still found ~49% new/worsened hypertension by sensitive criteria. Tumor lysis is the principal route to AKI; direct nephrotoxicity is case-level.MildEnzalutamideHypertension emerges over weeks to months of therapy.Hypertension is the dominant renovascular signal. A 2024 JAMA Oncology meta-analysis of androgen-receptor signaling inhibitors found a markedly increased risk of grade ≥3 hypertension (relative risk ~2.25); an earlier meta-analysis showed the same for enzalutamide specifically. Direct intrinsic kidney injury is uncommon; rare hyponatremia appears mainly in combination regimens. Reported rate: hypertension in 11.9% — Pooled analysis of 7 randomized clinical trials of enzalutamide in prostate cancer, 7347 patients (Zhu 2019, PMID 31557062).MildLeuprolideMonths to years (metabolic/cardiovascular and skeletal).No characteristic direct nephrotoxicity. Androgen-deprivation therapy is associated with metabolic syndrome, insulin resistance, dyslipidemia and increased cardiovascular disease, which raise long-term renovascular risk; a systematic review/meta-analysis confirms excess cardiovascular events with androgen-pathway therapy, and preclinical models show GnRH-agonist-induced metabolic syndrome and atherosclerosis. Reported rate: hypertension in 14.6% — 137 subjects with advanced prostate cancer indicated for androgen ablation, receiving leuprolide mesylate subcutaneous… (Shore 2020, PMID 30941562).MildAsciminibHypertension can emerge across treatment; pancreatitis often early.Hypertension and pancreatitis (with amylase/lipase elevations) are recognized toxicities; thrombocytopenia/neutropenia are common. In first-line use (ASC4FIRST), hypertension occurred more frequently with asciminib than comparator TKIs — all-grade 10.5%, grade >=3 5.5%. Asciminib has a cleaner overall profile than prior TKIs, and direct nephrotoxicity is not a defined signal — renal effects are largely hypertension-mediated.MildRipretinibHypertension can develop within early cycles and persist.Hypertension is the recognized renal-relevant toxicity: in the INVICTUS phase 3 trial (n=85), grade 3-4 hypertension occurred in 3 patients (4%) — the second most common grade 3-4 treatment-related event after lipase increase — alongside alopecia, palmar-plantar erythrodysesthesia, fatigue and myalgia. Direct nephrotoxicity is not a defined signal; renal effects are hypertension-mediated.Mild